Route | Form | Dose | Cmax (ng/mL) |
Tmax (hours) |
t1/2 (hours) | ||
---|---|---|---|---|---|---|---|
Oral | Capsule | 200 mg | 4.3–11.7 | 2–2.5 | ? | ||
Sublingual | Tablet[a] | 100 mg | 13.5 | 1–4 | ~6–7 | ||
Suspension | 100 mg | 17.6 | 0.5–1 | ? | |||
Vaginal | Tablet[a] | 100 mg | 10.9 | 6–7 | 13.7 | ||
Capsule | 100 mg | 9.7 | 1–3 | ? | |||
Intramuscular injection |
Oil solution | 50 mg | 14.3 | 8.7 | ? | ||
100 mg | 113 | 6.7 | 22.3 | ||||
Aq. solution[b] | 100 mg | 440 | 0.88 | 14.3 | |||
Subcutaneous injection |
Aq. solution[b] | 25 mg | 57.8 | 0.92 | 13.1 | ||
50 mg | 103 | 0.92 | 17.2 | ||||
100 mg | 235–300 | 0.92 | 17.2–17.6 | ||||
|
Template documentation
See also
References
- ^ Khomyak NV, Mamchur VI, Khomyak EV (2014). "Клинико-фармакологические особенности современных лекарственных форм микронизированного прогестерона, применяющихся во время беременности" [Clinical and pharmacological features of modern dosage forms of micronized progesterone used during pregnancy.] (PDF). Здоровье женщины (Women's Health) (in Russian) (4): 40–45.
- ^ Cometti B (November 2015). "Pharmaceutical and clinical development of a novel progesterone formulation". Acta Obstetricia et Gynecologica Scandinavica. 94 (Suppl 161): 28–37. doi:10.1111/aogs.12765. PMID 26342177.